These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18513392)

  • 21. [Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect].
    Erdmann E; Scherbaum WA
    MMW Fortschr Med; 2007 Dec; 149(49-50):49-50. PubMed ID: 18236983
    [No Abstract]   [Full Text] [Related]  

  • 22. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
    Singh S; Loke YK; Furberg CD
    JAMA; 2007 Sep; 298(10):1189-95. PubMed ID: 17848653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The rosiglitazone meta-analysis.
    McCullough PA; Lepor NE
    Rev Cardiovasc Med; 2007; 8(2):123-6. PubMed ID: 17603430
    [No Abstract]   [Full Text] [Related]  

  • 24. Good for women, good for men, bad for people: Simpson's paradox and the importance of sex-specific analysis in observational studies.
    Baker SG; Kramer BS
    J Womens Health Gend Based Med; 2001 Nov; 10(9):867-72. PubMed ID: 11747681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis of incidence of rare events.
    Lane PW
    Stat Methods Med Res; 2013 Apr; 22(2):117-32. PubMed ID: 22218366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis for rare events.
    Cai T; Parast L; Ryan L
    Stat Med; 2010 Sep; 29(20):2078-89. PubMed ID: 20623822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rosiglitazone and myocardial infarction: cause for concern or misleading meta-analysis?
    Bilous RW
    Diabet Med; 2007 Sep; 24(9):931-3. PubMed ID: 17725705
    [No Abstract]   [Full Text] [Related]  

  • 28. Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.
    Motola D; Piccinni C; Biagi C; Raschi E; Marra A; Marchesini G; Poluzzi E
    Drug Saf; 2012 Apr; 35(4):315-23. PubMed ID: 22376166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rosiglitazone and cardiovascular disease: a cardiologist's perspective.
    Marx N
    Diab Vasc Dis Res; 2007 Jun; 4(2):80-1. PubMed ID: 17654439
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.
    Loke YK; Kwok CS; Singh S
    BMJ; 2011 Mar; 342():d1309. PubMed ID: 21415101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simpson's paradox and clinical trials: what you find is not necessarily what you prove.
    Abramson NS; Kelsey SF; Safar P; Sutton-Tyrrell K
    Ann Emerg Med; 1992 Dec; 21(12):1480-2. PubMed ID: 1443848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simpson's Paradox is suppression, but Lord's Paradox is neither: clarification of and correction to Tu, Gunnell, and Gilthorpe (2008).
    Nickerson CA; Brown NJL
    Emerg Themes Epidemiol; 2019; 16():5. PubMed ID: 31788009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety of rosiglitazone in the treatment of type 2 diabetes.
    Singh S; Loke YK
    Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Simpson's paradox unraveled.
    Hernán MA; Clayton D; Keiding N
    Int J Epidemiol; 2011 Jun; 40(3):780-5. PubMed ID: 21454324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death.
    Shuster JJ; Jones LS; Salmon DA
    Stat Med; 2007 Oct; 26(24):4375-85. PubMed ID: 17768699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone.
    Hernandez AV; Walker E; Ioannidis JP; Kattan MW
    Am Heart J; 2008 Jul; 156(1):23-30. PubMed ID: 18585493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rosiglitazone and cardiovascular risk.
    Mannucci E; Monami M; Marchionni N
    N Engl J Med; 2007 Aug; 357(9):938; author reply 939-40. PubMed ID: 17806136
    [No Abstract]   [Full Text] [Related]  

  • 38. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review.
    Wang AT; McCoy CP; Murad MH; Montori VM
    BMJ; 2010 Mar; 340():c1344. PubMed ID: 20299696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.
    Wallach JD; Wang K; Zhang AD; Cheng D; Grossetta Nardini HK; Lin H; Bracken MB; Desai M; Krumholz HM; Ross JS
    BMJ; 2020 Feb; 368():l7078. PubMed ID: 32024657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simpson's paradox in psychological science: a practical guide.
    Kievit RA; Frankenhuis WE; Waldorp LJ; Borsboom D
    Front Psychol; 2013; 4():513. PubMed ID: 23964259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.